The new weekly 120 mg SC formulation, supported by TULIP-SC trial results, offers patients with moderate to severe SLE a self-administered alternative to monthly IV infusions.
Oncology nurse practitioners discuss CD38-based frontline therapy for newly diagnosed multiple myeloma, including Dara-VRd ...
The U.S. Food & Drug Administration (FDA) has granted approval for subcutaneous administration of anifrolumab (SAPHNELO) for ...
In Europe, the SC formulation of daratumumab, another anti-CD38 antibody, recently received a label update that allowed ...
The EFFISAYIL ON study demonstrated that IV spesolimab may be an effective rescue therapy for GPP patients on SC spesolimab who experience a GPP flare.
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The most common therapy, again, is ...
Learn how subcutaneous nivolumab shifts immunotherapy from IV infusions to quick thigh or abdominal injections, approved in late 2024. In this segment, Dr. Morrison introduces the concept of ...
For individuals living with cancer, navigating treatment can be a significant challenge, often requiring substantial time commitments and disruptions to daily life. Traditionally, immunotherapy ...
Since acquiring rare disease specialist Horizon Therapeutics in 2023 for $27.8 billion, Amgen has had difficulty boosting sales for the top product gained in the buyout, thyroid eye disease (TED) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results